Boehringer, Teva Sued Again Over Deal To Delay Generic

Law360, New York (January 6, 2014, 4:12 PM EST) -- Teva Pharmaceuticals USA Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were hit Monday with another proposed antitrust class action, this in Minnesota federal court, over an alleged pay-for-delay deal that kept a generic form of an anti-stroke medication off the market.

A health and welfare fund of the International Union of Painters and Allied Trades said Monday that indirect purchasers of the stroke-risk-reducing drug Aggrenox paid artificially high prices for it because of an anti-competitive deal between Boehringer and Teva subsidiary Barr Pharmaceuticals Inc.

It was at...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.